← Back to Search

Improvised Music for Alzheimer's Disease

N/A
Waitlist Available
Led By Borna Bonakdarpour, MD, FAAN
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion (3 years)
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to study the effects of a type of calming improvised music called Clinically Designed Improvisatory Music (CDIM) on reducing anxiety in both healthy individuals and Alzheimer's patients with anxiety.

Who is the study for?
This trial is for both cognitively healthy individuals and those with Alzheimer's Disease who experience anxiety. Participants must have a score greater than 8 on the Beck Anxiety Inventory (BAI), indicating some level of anxiety.
What is being tested?
The study tests Clinically Designed Improvisatory Music (CDIM) to see if it can reduce anxiety in people without cognitive issues and those with Alzheimer's Disease. The music used is improvised, calming, and doesn't depend on personal memories.
What are the potential side effects?
Since this intervention involves listening to music, side effects are minimal but may include discomfort or emotional distress due to the nature of improvisatory sounds.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion (3 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion (3 years) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Beck Anxiety Inventory [BAI-1: pre-intervention; BAI-2: post-intervention]
Change in Neuropsychiatric Inventory (NPI) [NPI-1: pre-intervention; NPI-2: post-intervention]
Secondary study objectives
Change Respiratory Rate [RR-1: pre-intervention; RR-2: post-intervention]
Body Weight Changes
Magnetic Resonance Imaging
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cognitively Healthy (CH)Experimental Treatment1 Intervention
Group II: Alzheimer Disease (AD)Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,649 Previous Clinical Trials
958,741 Total Patients Enrolled
Borna Bonakdarpour, MD, FAANPrincipal InvestigatorNorthwestern Mesulam Center for Cognitive Neurology and Alzheimer Disease
~11 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top